コカイン使用障害の世界市場 (治療アプローチ別、薬剤別、治療環境別、業種別)：将来予測 (2025～2030年)

コカイン使用障害市場は2023年に13億2,000万米ドルと評価され、2024年には13億9,000万米ドルに達すると予測され、CAGR 6.21%で成長し、2030年には20億1,000万米ドルになると予測されています。

コカイン使用障害 (CUD) は、臨床的に重大な障害や苦痛をもたらすコカインの強迫的使用を特徴とする重大な公衆衛生問題です。CUDの範囲には、主に製薬会社、研究機関、医療提供者、リハビリセンターが関与しており、CUDを対象とした治療や療法が開発されています。CUDに対処する必要性は、医療費用から生産性の低下、法的影響に至るまで、その社会的コストの高さによって強調されています。そのため、薬物補助治療、行動療法、遺伝子や神経生物学的研究を含む革新的アプローチなど、包括的な応用が求められています。最終用途は主に病院、リハビリテーション施設、さらには罹患者へのアウトリーチ拡大を目指す遠隔医療プラットフォームにまで及びます。

市場成長要因には、薬物使用障害に対する意識の高まり、医療インフラの強化、新規治療手法の継続的調査などが含まれます。CUDの社会的負担の増加は、進歩的な医療政策と相まって、より効果的な介入戦略への需要を後押ししています。この市場における治療機会は、デジタルヘルス技術とAI主導の個別化治療計画の統合によって強調されます。企業は、患者のアドヒアランスを監視・促進するためのモバイル・アプリケーションや、早期発見・予防戦略のためのAIツールに投資することができます。しかし、厳しい規制の枠組み、依存症を取り巻く社会的烙印、複雑な行動上の健康変数による臨床試験の課題などの制約が、市場の成長を阻害する可能性があります。

同市場は、神経調節技術の探求や、コカイン中毒に関与する特定の脳経路を標的とする非中毒性治療薬の開発など、技術革新のための有力な手段を提供しています。さらに、特にAIや機械学習に注力するハイテク企業との異業種コラボレーションは、研究開発イニシアチブを強化する可能性があります。コカイン中毒の多面的な側面の治療と理解の両方を目指した持続的なイノベーションと学際的なパートナーシップによって、かなりの可能性が活用されることになります。イニシアチブを世界・パートナーシップに拡大することで、地域格差を緩和し、市場の成熟を加速させることもできます。

市場力学：急速に進化するコカイン使用障害市場の主要市場インサイトを公開

コカイン使用障害市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のコカイン使用の蔓延
  • コカイン使用障害の治療が必要となる、中毒問題に対する認識と社会的受容の高まり
  • 依存症治療プログラムに対する政府および民間からの資金援助
• 市場抑制要因
  • 専門医療提供者の利用可能性の制限とコカイン中毒に関連する社会的スティグマ
• 市場機会
  • 遺伝子や心理社会的マーカーを活用した革新的医療アプローチによる個別化治療
  • 治療結果の予測における人工知能と機械学習の応用、およびデジタル・プラットフォームを通じた患者エンゲージメントの強化
• 市場の課題
  • 規制上のハードル、世界各地の集団における治療効果のばらつき

ポーターのファイブフォース：コカイン使用障害市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：コカイン使用障害市場における外部からの影響の把握

外部マクロ環境要因は、コカイン使用障害市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：コカイン使用障害市場における競合情勢の把握

コカイン使用障害市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：コカイン使用障害市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、コカイン使用障害市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：コカイン使用障害市場における成功への道筋を描く

コカイン使用障害市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

当レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1. 市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2. 市場の発展度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3. 市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4. 競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5. 製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1. 現在の市場規模と今後の成長予測は？

2. 最高の投資機会を提供する製品、セグメント、地域はどこか？

3. 市場を形成する主な技術動向と規制の影響とは？

4. 主要ベンダーの市場シェアと競合ポジションは？

5. ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序論

第2章 分析手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でコカイン使用が増加
    • 依存症問題に対する認識と社会的受容が高まり、コカイン使用障害の治療が必要となる
    • 依存症治療プログラムに対する官民の資金提供
  • 抑制要因
    • 専門の医療提供者の不足とコカイン中毒に関連する社会的偏見
  • 機会
    • 遺伝的・心理社会的マーカーを活用して個別化された治療を行う、革新的な医療アプローチ
    • 人工知能と機械学習を応用して治療結果を予測し、デジタルプラットフォームを通じて患者のエンゲージメントを強化する
  • 課題
    • 規制上のハードルと世界中の人口における治療効果のばらつき
• 市場セグメンテーション分析
  • 治療環境：住宅リハビリテーション施設への関心が高まっている
  • 薬剤：コカイン使用障害の治療における精神刺激薬の必要性に基づく選好
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的要因
  • 経済的要因
  • 社会的要因
  • 技術的要因
  • 法的要因
  • 環境的要因

第6章 コカイン使用障害の市場治療：治療アプローチ別

• 行動療法
• 認知行動療法
• 不測事態管理
• 薬物療法による治療
• モチベーションの向上

第7章 コカイン使用障害の市場：薬剤別

• 抗けいれん薬
• 抗うつ薬
• 抗精神病薬
• 精神刺激薬

第8章 コカイン使用障害市場：治療環境別

• 病院ベースの治療プログラム
• 入院リハビリテーションセンター
• 通所リハビリテーションセンター
• 在宅リハビリテーション施設

第9章 南北アメリカのコカイン使用障害の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のコカイン使用障害の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのコカイン使用障害の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析 (2023年)
• FPNVポジショニングマトリックス (2023年)
• 競合シナリオ分析
  • 科学者がコカインのワクチンを開発
  • FDA、オピオイド使用障害に対する新たなブプレノルフィン治療オプションを承認
• 戦略分析と提言

企業一覧

• Alkermes PLC
• Alnylam Pharmaceuticals, Inc.
• Camurus AB
• Indivior PLC
• Johnson & Johnson Services, Inc.
• KemPharm, Inc.
• Novartis International AG
• Orexo AB
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Revive Therapeutics Ltd.
• Sage Therapeutics, Inc.
• Shionogi & Co., Ltd.
• Teva Pharmaceuticals USA, Inc.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. COCAINE USE DISORDER MARKET RESEARCH PROCESS
• FIGURE 2. COCAINE USE DISORDER MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL COCAINE USE DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. COCAINE USE DISORDER MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. COCAINE USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. COCAINE USE DISORDER MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL COCAINE USE DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. COCAINE USE DISORDER MARKET DYNAMICS
• TABLE 7. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY CONTINGENCY MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MEDICATION-ASSISTED TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY PSYCHOSTIMULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY HOSPITAL-BASED TREATMENT PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY INPATIENT REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY OUTPATIENT REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL COCAINE USE DISORDER MARKET SIZE, BY RESIDENTIAL REHABILITATION FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 33. CANADA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 34. CANADA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 35. CANADA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES COCAINE USE DISORDER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 50. CHINA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 51. CHINA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 52. CHINA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 53. INDIA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 54. INDIA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 55. INDIA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA COCAINE USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 105. ITALY COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 106. ITALY COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 107. ITALY COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 117. POLAND COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 118. POLAND COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 119. POLAND COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 120. QATAR COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 121. QATAR COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 122. QATAR COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM COCAINE USE DISORDER MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM COCAINE USE DISORDER MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM COCAINE USE DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
• TABLE 150. COCAINE USE DISORDER MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. COCAINE USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

The Cocaine Use Disorder Market was valued at USD 1.32 billion in 2023, expected to reach USD 1.39 billion in 2024, and is projected to grow at a CAGR of 6.21%, to USD 2.01 billion by 2030.

Cocaine Use Disorder (CUD) is a significant public health issue characterized by the compulsive use of cocaine, leading to clinically significant impairment or distress. Its market scope primarily involves pharmaceutical companies, research institutions, healthcare providers, and rehabilitation centers developing treatments and therapies targeted at CUD. The necessity of addressing CUD is underscored by its high societal costs, ranging from healthcare expenses to lost productivity and legal implications. This calls for comprehensive applications, such as medication-assisted treatments, behavioral therapies, and innovative approaches involving genetic and neurobiological research. End-use primarily spans hospitals, rehabilitation facilities, and even telemedicine platforms aiming to expand outreach for affected individuals.

Market growth factors include increasing awareness about substance use disorders, enhanced healthcare infrastructure, and ongoing research into novel treatment methodologies. The rising societal burden of CUD, combined with progressive healthcare policies, propels the demand for more effective intervention strategies. Opportunities in this market are highlighted by the integration of digital health technologies and AI-driven personalized treatment plans. Companies could invest in mobile applications for monitoring and encouraging patient adherence or AI tools for early detection and prevention strategies. However, limitations such as stringent regulatory frameworks, the social stigma surrounding addiction, and challenges in clinical trials due to complex behavioral health variables may impede market growth.

The market offers prime avenues for innovation, including the exploration of neuromodulation techniques and the development of non-addictive therapeutics that target specific brain pathways involved in cocaine addiction. Furthermore, cross-industry collaborations, especially with tech firms focusing on AI and machine learning, could bolster research and development initiatives. The nature of the market is one of cautious optimism, with considerable potential harnessed through sustained innovation and multi-disciplinary partnerships aimed at both treating and understanding the multifaceted aspects of cocaine addiction. Expanding initiatives to include global partnerships can also alleviate regional disparities and accelerate market maturity.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cocaine Use Disorder Market

The Cocaine Use Disorder Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of cocaine use worldwide
  • Increasing awareness and social acceptance of addiction issues, necessitating the treatments for cocaine use disorders
  • Governmental and private funding for addiction treatment programs
• Market Restraints
  • Limited availability of specialized healthcare providers and social stigmas associated with cocaine addiction
• Market Opportunities
  • Innovative medicine approaches utilizing genetic and psychosocial markers to tailor personalized treatments
  • Application of artificial intelligence and machine learning in predicting treatment outcomes and enhancements in patient engagement through digital platforms
• Market Challenges
  • Regulatory hurdles and variability in treatment effectiveness across populations worldwide

Porter's Five Forces: A Strategic Tool for Navigating the Cocaine Use Disorder Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cocaine Use Disorder Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cocaine Use Disorder Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cocaine Use Disorder Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cocaine Use Disorder Market

A detailed market share analysis in the Cocaine Use Disorder Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cocaine Use Disorder Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cocaine Use Disorder Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cocaine Use Disorder Market

A strategic analysis of the Cocaine Use Disorder Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cocaine Use Disorder Market, highlighting leading vendors and their innovative profiles. These include Alkermes PLC, Alnylam Pharmaceuticals, Inc., Camurus AB, Indivior PLC, Johnson & Johnson Services, Inc., KemPharm, Inc., Novartis International AG, Orexo AB, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Revive Therapeutics Ltd., Sage Therapeutics, Inc., Shionogi & Co., Ltd., Teva Pharmaceuticals USA, Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cocaine Use Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapeutic Approaches, market is studied across Behavioral Therapies, Cognitive-Behavioral Therapy, Contingency Management, Medication-Assisted Treatment, and Motivational Enhancement.
• Based on Medications, market is studied across Anticonvulsants, Antidepressants, Antipsychotics, and Psychostimulants.
• Based on Treatment Setting, market is studied across Hospital-Based Treatment Programs, Inpatient Rehabilitation Centers, Outpatient Rehabilitation Centers, and Residential Rehabilitation Facilities.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of cocaine use worldwide
    • 5.1.1.2. Increasing awareness and social acceptance of addiction issues, necessitating the treatments for cocaine use disorders
    • 5.1.1.3. Governmental and private funding for addiction treatment programs
  • 5.1.2. Restraints
    • 5.1.2.1. Limited availability of specialized healthcare providers and social stigmas associated with cocaine addiction
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovative medicine approaches utilizing genetic and psychosocial markers to tailor personalized treatments
    • 5.1.3.2. Application of artificial intelligence and machine learning in predicting treatment outcomes and enhancements in patient engagement through digital platforms
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory hurdles and variability in treatment effectiveness across populations worldwide
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Setting: Increasing preference for residential rehabilitation facilities
  • 5.2.2. Medications: Need based preference for psychostimulants for treatment of cocaine use disorder
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cocaine Use Disorder Market, by Therapeutic Approaches

• 6.1. Introduction
• 6.2. Behavioral Therapies
• 6.3. Cognitive-Behavioral Therapy
• 6.4. Contingency Management
• 6.5. Medication-Assisted Treatment
• 6.6. Motivational Enhancement

7. Cocaine Use Disorder Market, by Medications

• 7.1. Introduction
• 7.2. Anticonvulsants
• 7.3. Antidepressants
• 7.4. Antipsychotics
• 7.5. Psychostimulants

8. Cocaine Use Disorder Market, by Treatment Setting

• 8.1. Introduction
• 8.2. Hospital-Based Treatment Programs
• 8.3. Inpatient Rehabilitation Centers
• 8.4. Outpatient Rehabilitation Centers
• 8.5. Residential Rehabilitation Facilities

9. Americas Cocaine Use Disorder Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cocaine Use Disorder Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cocaine Use Disorder Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Scientists Develop a Vaccine For Cocaine
  • 12.3.2. FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alkermes PLC
• 2. Alnylam Pharmaceuticals, Inc.
• 3. Camurus AB
• 4. Indivior PLC
• 5. Johnson & Johnson Services, Inc.
• 6. KemPharm, Inc.
• 7. Novartis International AG
• 8. Orexo AB
• 9. Otsuka Pharmaceutical Co., Ltd.
• 10. Pfizer Inc.
• 11. Revive Therapeutics Ltd.
• 12. Sage Therapeutics, Inc.
• 13. Shionogi & Co., Ltd.
• 14. Teva Pharmaceuticals USA, Inc.
• 15. Viatris Inc.